Posts by Catalin Radu

Ten years. For some, that’s how long you suffered with DADA2 symptoms before receiving a diagnosis. Decades of searching and treatment trials is certainly the case for my family.

BUT, ten years is also the milestone the Foundation has reached since our founding. Just two years after DADA2 was officially named a disease, the Foundation formed and held our first conference in 2016 and I cannot begin to tell you all that we have accomplished – together – as we move toward a cure.

As we head into the new year, we are hopeful that new scientific discoveries and increased support for newly diagnosed patients and their physicians will ultimately improve the lives of patients and help identify the undiagnosed. We invite you to be a part of this important mission with a one-time or monthly gift. Your generous contribution of any size is critical to continue all of the work you see below.

Are you READY to join us?

Every time I connect with members of our DADA2 community, I’m reminded that this journey is shared. Each family’s story of searching for answers, finding the right care, and learning to adapt helps guide the work we do together.

As we enter the heart of summer, I’m excited to share some important updates from the DADA2 Foundation. This season’s newsletter highlights the incredible momentum we’re seeing across the global DADA2 community — from growing international partnerships and new treatment possibilities, to cutting-edge research expanding our understanding of the ADA2 enzyme.

April has given me a chance to reflect on the growth of what I often call my youngest “child”—the DADA2 Foundation. Like any parent watching their children come into their own, there comes a time when you realize they no longer need constant guidance; they begin to find their own path, form new connections, and make an impact beyond your immediate reach.

That’s exactly how I felt while reviewing all the DADA2-related content presented at this month’s ISSAID conference in Paris.

Spring has arrived in the southern United States, bringing its signature unpredictability—one moment warm and glorious, the next stormy and cold. In many ways, this mirrors the uncertainty in the political landscape, where funding for rare disease research remains in flux. The Foundation is closely monitoring developments and advocating for continued support. While it’s still too early to determine the full impact on current and future grant funding, we remain steadfast in our mission.

As we approach Rare Disease Day 2025, I find myself reflecting on how far we’ve come. It was just 11 years ago this month that DADA2 was officially recognized as a rare disease. While we are all too familiar with the challenges faced by rare disease families, Rare Disease Day is also a time to acknowledge the strength, progress, and sense of community that have emerged from our shared journeys. To borrow the words of a new member of our community, visual artist Ellie Pritts, these past 11 years have truly been “a journey of adaptation and resilience.”

Happy New Year! I hope everyone had a joyful and relaxing holiday season. The start of a new year is always an opportunity to reflect on past accomplishments and set goals for the future. With that in mind, I want to extend a heartfelt THANK YOU to everyone who contributed so generously to our end-of-year giving campaign. Thanks to your support, the Foundation met our fundraising goal, and we begin 2025 with renewed confidence to continue our vital work

I am breaking with our standard newsletter format to share an incredible development in our 10 years of DADA2 research.

2024 marks ten years since researchers in Israel and the National Institutes of Health (NIH) in Bethesda, MD, first identified the genetic basis of Deficiency of Adenosine Deaminase 2 (DADA2). For many of us, however, that breakthrough in February 2014 was simply giving a name and genetic origin to a disease we had been living with for years.

The heat of Nashville’s summer has given way to the cooler temperatures of fall. Fall is always a time for me to reflect on where we have been and start thinking about where we are going. When I started the Foundation, it was with one goal in mind: to find a cure. The Foundation has successfully built an engaged network of patients, families, physicians and researchers, pushing our understanding of the disease forward in leaps and bounds. What do we need now? To be blunt, money. We will need to raise money – big and small amounts – to reach our goal.